Bellus Health Inc. (NYSE:BLU) Given Average Rating of “Buy” by Brokerages

Shares of Bellus Health Inc. (NYSE:BLU) have received a consensus recommendation of “Buy” from the six brokerages that are covering the firm, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $16.00.

Several research analysts recently weighed in on the company. Guggenheim assumed coverage on Bellus Health in a research report on Monday, September 30th. They issued a “buy” rating and a $12.00 price objective for the company. JBL Advisors assumed coverage on Bellus Health in a research report on Monday, September 30th. They issued a “buy” rating for the company. Cowen assumed coverage on Bellus Health in a research report on Monday, September 30th. They issued an “outperform” rating for the company. Jefferies Financial Group assumed coverage on Bellus Health in a research report on Monday, September 30th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, TheStreet upgraded Bellus Health from a “d+” rating to a “c-” rating in a research report on Friday, January 3rd.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. purchased a new position in shares of Bellus Health during the third quarter worth $257,000. Millennium Management LLC purchased a new position in shares of Bellus Health during the third quarter worth $424,000. Finally, Orbimed Advisors LLC purchased a new position in shares of Bellus Health during the third quarter worth $45,129,000.

Bellus Health stock traded up $0.10 during mid-day trading on Tuesday, hitting $8.63. The company’s stock had a trading volume of 103,500 shares, compared to its average volume of 334,833. Bellus Health has a 1 year low of $2.63 and a 1 year high of $9.36. The business has a fifty day moving average price of $7.38.

Bellus Health (NYSE:BLU) last issued its quarterly earnings data on Thursday, November 14th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million.

About Bellus Health

BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.

Featured Article: Buy Rating

Analyst Recommendations for Bellus Health (NYSE:BLU)

Receive News & Ratings for Bellus Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellus Health and related companies with MarketBeat.com's FREE daily email newsletter.